Results 81 to 90 of about 299,964 (312)

Zuranolone: A case study in (regulatory) rush to judgement?

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove   +4 more
wiley   +1 more source

Alcohol use and sexual risk behaviors in the Armed Forces of the Democratic Republic of the Congo

open access: yesBMC Public Health, 2019
Background Alcohol misuse is an important contributor to sexual acquisition and transmission of HIV in military communities. This cross-sectional study quantified the prevalence of probable problematic alcohol use among male service members in the Armed ...
Bonnie Robin Tran   +5 more
doaj   +1 more source

Do drugs approved via expedited approval pathways have therapeutic advantages? A systematic review and meta‐analysis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Regulators use expedited approval pathways to speed market approval and patient access to promising new drugs. However, there is uncertainty about whether these pathways are successful in approving drugs with significant therapeutic advantages. This systematic review aims to examine the safety, effectiveness and cost‐effectiveness of drugs approved via
Ashleigh Hooimeyer   +4 more
wiley   +1 more source

HIV prevention in the south [PDF]

open access: yes
CDC allocates resources for HIV prevention interventions to populations most affected by HIV.cdc-hiv-prevention-south ...

core  

Precision medicine in paediatrics: Progress and priorities

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Precision medicine is revolutionizing personalized healthcare, advancing both diagnostics and therapeutics at an unprecedented pace. Reviewing the paediatric applications of pharmacometrics, pharmacogenomics and advanced therapy medicinal products highlights not only the relevance of these exciting innovations to frontline care but also the significant
Nicola Husain   +3 more
wiley   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

open access: yes, 2022
Hepatology, EarlyView.
Robert J. Fontana   +6 more
wiley   +1 more source

Methamphetamine use and risk for HIV/AIDS [PDF]

open access: yes
Produced by the National Center for HIV, STD, and TB Prevention Division of HIV/AIDS Prevention."January 2007."Mode of access: Internet from CDC web site.
National Center for HIV, STD, and TB Prevention (U.S.) Division of HIV/AIDS Prevention.
core  

British National Formulary Guidance on prescribing in pregnancy: A descriptive cross‐sectional study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim To assess how well pregnancy‐specific guidance within the British National Formulary supports healthcare professionals to facilitate safe and effective medication use. Methods We performed a manifest content analysis of the text of all pregnancy sections within British National Formulary drug monographs, with inductive and iterative coding.
Hannah Johnson   +9 more
wiley   +1 more source

HIV Planning Guidance [PDF]

open access: yes
On July 13, 2010, the White House released the National HIV/AIDS Strategy (NHAS). This ambitious plan is the nation's first-ever comprehensive coordinated HIV/AIDS roadmap with clear and measurable targets.

core  

Poor post‐exposure prophylaxis completion despite improvements in post‐violence service delivery in 14 PEPFAR‐supported sub‐Saharan African countries, 2018–2023

open access: yesJournal of the International AIDS Society
Introduction Sexual violence (SV) affects millions globally and has a well‐documented bidirectional association with HIV. Post‐exposure prophylaxis (PEP) is a critical, yet often underutilized, HIV prevention tool in post‐SV care.
Udhayashankar Kanagasabai   +23 more
doaj   +1 more source

Home - About - Disclaimer - Privacy